Macrogenics Inc (MGNX) 19.86 $MGNX
MacroGenics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 9:13AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO, and Jim Karrels, Vice President and Chief Financial Officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The presentation will take place Tuesday, May 13, 2014, at 5:00 p.m. Pacific Time in Las Vegas, NV.
MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Clinical study of first DART, MGD006, to commence in Second Quarter 2014
CMC Biologics and MacroGenics Enter into a Process Development and Manufacturing Agreement for Oncology Product Candidate
PR Newswire Europe - Tue May 06, 4:01AM CDT
CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.
MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014
GlobeNewswire - Mon May 05, 1:30PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data on MGD010, a bi-specific Dual-Affinity Re-targeting (DART(R)) protein, demonstrating its ability to inhibit B-cell activation without B-cell depletion, which could provide a novel treatment option for patients with autoimmune disorders. MGD010 also was shown to inhibit the development of graft-versus-host disease in a humanized murine model, a system amenable to ascertain the activity of immunomodulatory intervention. These data were presented at IMMUNOLOGY 2014, the American Association of Immunologists' Annual Meeting, in Pittsburgh, PA.
MacroGenics Appoints Atul Saran as Senior Vice President and General Counsel
GlobeNewswire - Wed Apr 30, 7:00AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has appointed Atul Saran as Senior Vice President and General Counsel. Mr. Saran most recently held a leadership role at AstraZeneca as Vice President, Corporate Development and Ventures, and also chaired the MedImmune Ventures Investment Committee.
MacroGenics Announces Date of First Quarter 2014 Financial Results Conference Call
GlobeNewswire - Tue Apr 29, 3:46PM CDT
MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, May 6, 2014, the Company will release its financial results for the quarter ended March 31, 2014. The Company's management team will host a conference call discussing the Company's financial results and recent developments on Tuesday, May 6, 2014 at 4:30 pm (EDT). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 35495095.
MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014
GlobeNewswire - Mon Apr 28, 4:00PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it will present pre-clinical data on its novel DART(R) candidate for the treatment of autoimmune disorders, MGD010, at IMMUNOLOGY 2014, the American Association of Immunologists Annual Meeting, in Pittsburgh, PA. The poster, titled "Development of human B-lymphocyte targeted bi-specific DART(R) molecules for the treatment of autoimmune disorders," will be presented Monday, May 5, 2014, from 2:30-3:45 pm ET in Hall A, poster THER5P.830, abstract number 200.9.
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
MacroGenics (MGNX) Jumps: Stock Up 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 8:39AM CDT
MacroGenics, Inc. was a big mover last session, as its shares rose nearly 8% on the day.
3 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Apr 24, 8:32AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Biotech stocks have been in near free-fall the past month, with the iShares Nasdaq Biotechnology Index dropping a noteworthy 15.4%. While this could be part of a general market correction, such a dramatic decline may indicate deeper issues with...
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
PolyTherics and MacroGenics Extend Collaboration to Produce Novel Antibody Drug Conjugates
PR Newswire Europe - Fri Apr 11, 5:42AM CDT
LONDON, April 11, 2014 /PRNewswire/ --
3 Stocks Spiking on Unusual Volume
at The Street - Thu Apr 10, 8:28AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting
GlobeNewswire - Sun Apr 06, 3:00PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data demonstrating that MGD007, a dual-affinity re-targeting (DART(R)) protein, has potent activity against colorectal cancer cells both in vitro and in vivo. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
MacroGenics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 7:01AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim Karrels, Vice President and Chief Financial Officer, and Eric Risser, Vice President of Business Development, will present at the 13 Annual Needham Healthcare Conference. The presentation will take place Tuesday, April 8, 2014, at 5:00 p.m. Eastern Time in New York.
MacroGenics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 9:13AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO, and Jim Karrels, Vice President and Chief Financial Officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The presentation will take place Tuesday, May 13, 2014, at 5:00 p.m. Pacific Time in Las Vegas, NV.
MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Clinical study of first DART, MGD006, to commence in Second Quarter 2014
CMC Biologics and MacroGenics Enter into a Process Development and Manufacturing Agreement for Oncology Product Candidate
PR Newswire Europe - Tue May 06, 4:01AM CDT
CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.
MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014
GlobeNewswire - Mon May 05, 1:30PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data on MGD010, a bi-specific Dual-Affinity Re-targeting (DART(R)) protein, demonstrating its ability to inhibit B-cell activation without B-cell depletion, which could provide a novel treatment option for patients with autoimmune disorders. MGD010 also was shown to inhibit the development of graft-versus-host disease in a humanized murine model, a system amenable to ascertain the activity of immunomodulatory intervention. These data were presented at IMMUNOLOGY 2014, the American Association of Immunologists' Annual Meeting, in Pittsburgh, PA.
MacroGenics Appoints Atul Saran as Senior Vice President and General Counsel
GlobeNewswire - Wed Apr 30, 7:00AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has appointed Atul Saran as Senior Vice President and General Counsel. Mr. Saran most recently held a leadership role at AstraZeneca as Vice President, Corporate Development and Ventures, and also chaired the MedImmune Ventures Investment Committee.
MacroGenics Announces Date of First Quarter 2014 Financial Results Conference Call
GlobeNewswire - Tue Apr 29, 3:46PM CDT
MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, May 6, 2014, the Company will release its financial results for the quarter ended March 31, 2014. The Company's management team will host a conference call discussing the Company's financial results and recent developments on Tuesday, May 6, 2014 at 4:30 pm (EDT). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 35495095.
MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014
GlobeNewswire - Mon Apr 28, 4:00PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it will present pre-clinical data on its novel DART(R) candidate for the treatment of autoimmune disorders, MGD010, at IMMUNOLOGY 2014, the American Association of Immunologists Annual Meeting, in Pittsburgh, PA. The poster, titled "Development of human B-lymphocyte targeted bi-specific DART(R) molecules for the treatment of autoimmune disorders," will be presented Monday, May 5, 2014, from 2:30-3:45 pm ET in Hall A, poster THER5P.830, abstract number 200.9.
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
MacroGenics (MGNX) Jumps: Stock Up 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 8:39AM CDT
MacroGenics, Inc. was a big mover last session, as its shares rose nearly 8% on the day.
3 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Apr 24, 8:32AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Biotech stocks have been in near free-fall the past month, with the iShares Nasdaq Biotechnology Index dropping a noteworthy 15.4%. While this could be part of a general market correction, such a dramatic decline may indicate deeper issues with...
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
PolyTherics and MacroGenics Extend Collaboration to Produce Novel Antibody Drug Conjugates
PR Newswire Europe - Fri Apr 11, 5:42AM CDT
LONDON, April 11, 2014 /PRNewswire/ --
3 Stocks Spiking on Unusual Volume
at The Street - Thu Apr 10, 8:28AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting
GlobeNewswire - Sun Apr 06, 3:00PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data demonstrating that MGD007, a dual-affinity re-targeting (DART(R)) protein, has potent activity against colorectal cancer cells both in vitro and in vivo. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
MacroGenics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 7:01AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim Karrels, Vice President and Chief Financial Officer, and Eric Risser, Vice President of Business Development, will present at the 13 Annual Needham Healthcare Conference. The presentation will take place Tuesday, April 8, 2014, at 5:00 p.m. Eastern Time in New York.
